FKFrank Kunath

Frank Kunath

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Frank Kunath has a total of 416 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of Recipient Variables on Transplant Survival Following Marginal Kidney Donation: Analysis of a Mate Kidney Cohort

    by Ariadni Androvitsanea, Katharina M. Heller, Hendrik Apel, Frank Kunath, Peter J. Goebell, Bernd Wullich, Ulrich Rother, Christoph Daniel, Kerstin Amann, Carsten Willam, et al.

    BACKGROUND Transplantation using kidneys from older donors or those with specific risk factors (marginal kidneys) offers improved outcomes compared to remaining on dialysis. Matched-pair analysis potentiates control for confounding donor factors and the impact of recipient characteristics on transplant survival. MATERIAL AND METHODS Data from 200 transplants using marginal deceased donors were retrospectively analyzed. Paired comparisons between mate kidney recipients, McNemar's test, and multivariable Cox regression were performed to identify recipient factors and histological features from zero-time biopsy associated with graft survival. RESULTS Graft survival was significantly longer in recipients with shorter pre-transplant dialysis exposure (mean 58.10 vs 68.86 months, P=0.001) and fewer HLA mismatches (3.40 vs 3.78, P=0.013). Severe acute tubular injury (ATI) in pre-implantation biopsy was associated with reduced graft survival (P=0.04). In multivariable Cox regression, the presence of severe ATI (P<0.001), older recipient age (HR=0.1 per year, P=0.002), HLA mismatches (HR=1.21, P=0.011), and elevated 1-year serum creatinine level (HR=0.72, P=0.030) remained independently associated with shorter graft survival. CONCLUSIONS Matched-pair analysis and multivariable modelling identified recipient dialysis duration, age, HLA mismatches,1-year serum creatinine, and pre-transplant biopsy findings, particularly severe ATI, as key predictors of graft survival in marginal kidney transplantation. These insights may support improved recipient selection and post-transplant management of marginal-donor kidneys.


  • Cytoreductive nephrectomy in metastatic renal cell carcinoma

    by Philipp Dahm, Onuralp Ergun, Annemarie Uhlig, Laura Bellut, Michael C Risk, Jennifer A Lyon, Frank Kunath

    Background Nephrectomy is the surgical removal of all or part of a kidney. When the aim of nephrectomy is to reduce tumor burden in people with established metastatic disease, the procedure is called cytoreductive nephrectomy (CN). CN is typically combined with systemic anticancer therapy (SACT). SACT can be initiated before or immediately after the operation or deferred until radiological signs of disease progression. The benefits and harms of CN are controversial. Objectives To assess the effects of cytoreductive nephrectomy combined with systemic anticancer therapy versus systemic anticancer therapy alone or watchful waiting in newly diagnosed metastatic renal cell carcinoma. Search methods We performed a comprehensive search in the Cochrane Library, MEDLINE, Embase, Scopus, two trial registries, and other gray literature sources up to 1 March 2024. We applied no restrictions on publication language or status. Selection criteria We included randomized controlled trials (RCTs) that evaluated SACT and CN versus SACT alone or watchful waiting. Data collection and analysis Two review authors independently selected studies and extracted data. Primary outcomes were time to death from any cause and quality of life. Secondary outcomes were time to disease progression, treatment response, treatment‐related mortality, discontinuation due to adverse events, and serious adverse events. We performed statistical analyses using a random‐effects model. We rated the certainty of evidence using the GRADE approach. Main results Our search identified 10 records of four unique RCTs that informed two comparisons. In this abstract, we focus on the results for the two primary outcomes. Cytoreductive nephrectomy plus systemic anticancer therapy versus systemic anticancer therapy alone Three RCTs informed this comparison. Due to the considerable heterogeneity when pooling across these studies, we decided to present the results of the prespecified subgroup analysis by type of systemic agent. Cytoreductive nephrectomy plus interferon immunotherapy versus interferon immunotherapy alone CN plus interferon immunotherapy compared with interferon immunotherapy alone probably increases time to death from any cause (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.51 to 0.89; I²= 0%; 2 studies, 326 participants; moderate‐certainty evidence). Assuming 820 all‐cause deaths at two years' follow‐up per 1000 people who receive interferon immunotherapy alone, the effect estimate corresponds to 132 fewer all‐cause deaths (237 fewer to 37 fewer) per 1000 people who receive CN plus interferon immunotherapy. We found no evidence to assess quality of life. Cytoreductive nephrectomy plus tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone We are very uncertain about the effect of CN plus tyrosine kinase inhibitor (TKI) therapy compared with TKI therapy alone on time to death from any cause (HR 1.11, 95% CI 0.90 to 1.37; 1 study, 450 participants; very low‐certainty evidence). Assuming 574 all‐cause deaths at two years' follow‐up per 1000 people who receive TKI therapy alone, the effect estimate corresponds to 38 more all‐cause deaths (38 fewer to 115 more) per 1000 people who receive CN plus TKI therapy. We found no evidence to assess quality of life. Immediate cytoreductive nephrectomy versus deferred cytoreductive nephrectomy One study evaluated CN followed by TKI therapy (immediate CN) versus three cycles of TKI therapy followed by CN (deferred CN). Immediate CN compared with deferred CN may decrease time to death from any cause (HR 1.63, 95% CI 1.05 to 2.53; 1 study, 99 participants; low‐certainty evidence). Assuming 620 all‐cause deaths at two years' follow‐up per 1000 people who receive deferred CN, the effect estimate corresponds to 173 more all‐cause deaths (18 more to 294 more) per 1000 people who receive immediate CN. We found no evidence to assess quality of life. Authors' conclusions CN plus SACT in the form of interferon immunotherapy versus SACT in the form of interferon immunotherapy alone probably increases time to death from any cause. However, we are very uncertain about the effect of CN plus SACT in the form of TKI therapy versus SACT in the form of TKI therapy alone on time to death from any cause. Immediate CN versus deferred CN may decrease time to death from any cause. We found no quality of life data for any of these three comparisons. We also found no evidence to inform any other comparisons, in particular those involving newer immunotherapy agents (programmed death receptor 1 [PD‐1]/programmed death ligand 1 [PD‐L1] immune checkpoint inhibitors), which have become the backbone of SACT for metastatic renal cell carcinoma. There is an urgent need for RCTs that explore the role of CN in the context of contemporary forms of systemic immunotherapy.


  • Kommentar zu: Übersichtsarbeiten in der Urologie: Qualität der Literatursuche oft mangelhaft

    by Frank Kunath

    Wie erfolgt die Suche in systematischen Übersichtsarbeiten? Diese sehr wichtige Fragestellung hat die Arbeitsgruppe um Prof. Dr. Philipp Dahm untersucht. Er ist nicht nur Urologe, sondern auch der ‚Coordinating Editor‘ von Cochrane Urology. Die Arbeitsgruppe verfügt über weitreichende Erfahrungen in der Durchführung und methodischen Beurteilung von systematischen Übersichtsarbeiten. Die Methodik der hier vorgestellten Arbeit folgte den in der evidenzbasierten Medizin üblichen Vorgehensweise und untersuchte die methodische Qualität der Literatursuche von systematischen Übersichtsarbeiten in den wichtigen Urologischen Fachzeitschriften (BJU International, European Urology, The Journal of Urology, Urology und World Journal of Urology). Warum ist das eine wichtige Fragestellung? Idealerweise sollten medizinische Entscheidungen auf Studienergebnissen basieren. Für klinisch tätige Ärzte ist es aber aufgrund der enormen Anzahl an Publikationen in den biomedizinischen Datenbanken schwierig auf dem aktuellen Wissensstand zu bleiben. Systematische Übersichtsarbeiten fassen die medizinische Literatur zusammen und bewerten deren methodische Qualität. Diese Arbeiten dienen schließlich als Grundlage zur Erstellung von evidenzbasierten Handlungsempfehlungen. Die Methodik einer systematischen Übersichtsarbeit ist somit die Basis für den Wissenstransfer aus der klinischen Forschung an das Patientenbett. Die Autoren konnten zeigen, dass auch Publikationen in den anerkanntesten urologischen Fachzeitschriften relevante methodische Schwächen haben können. Systematische Übersichtsarbeiten mit methodischen Schwächen bergen das Risiko, dass neu entwickelte medizinische Handlungen ohne ausreichende Nutzen-/Schadensprüfung angewendet werden. Basieren Leitlinienempfehlung auf den Ergebnissen einer qualitativ schlechten systematischen Übersichtsarbeit, dann hat dies direkten Einfluss auf die Patientenbetreuung in der klinischen Routine. In der Arbeit wurden die formalen Aspekte der durchgeführten Literatursuche analysiert (Anzahl verschiedener Datenbanken, Filter in der Suchstrategie usw.). Ein wichtiger Aspekt blieb in der Auswertung aber unberücksichtigt. Es wurde nicht untersucht, ob ein Suchspezialist in der Erstellung der Suchstrategie beteiligt war und wie der eigentliche methodische Aufbau der Suchstrategie war. Die Suchstrategie ist sicherlich ein wichtiger Aspekt bei der Betrachtung von systematischen Übersichtsarbeiten, aber es ist ebenso relevant die Qualität der eingeschlossenen Studie zu beurteilen (sogenannte ‚risk of bias‘-Analyse). Es bleibt unklar, warum dies in der vorliegenden Arbeit nicht gemacht wurde. Vielleicht werden diese Ergebnisse in weiteren Publikationen veröffentlicht. Es wurden systematische Übersichtsarbeiten von 1998–2021 eingeschlossen und die heutigen Ansichten für qualitativ hochwertige systematische Übersichtsarbeiten retrospektiv auf die Arbeiten der letzten 20 Jahre angewendet. Dieses Vorgehen wird von den Autoren selbst kritisch diskutiert. Bei der Evaluierung von Volltextpublikationen bleibt letztlich unklar, ob die eingeschlossenen systematischen Übersichtsarbeiten tatsächlich methodische Limitationen hatten. Denkbar ist auch, dass das methodische Vorgehen bei der Literatursuche korrekt, aber die Berichterstattung in der Publikation unvollständig war. Für den Wissenstransfer können aber beide Optionen relevante Auswirkungen haben. Die wichtigste Aussage dieser Arbeit ist, dass eine Publikation in einer anerkannten Fachzeitschrift durchaus kritisch gelesen werden sollte. Es ist unabdingbar, dass ein klinisch tätiger Arzt die methodische Qualität einer klinischen Studie und einer systematischen Übersichtsarbeit selbstständig einschätzen kann. In der medizinischen Ausbildung sollte dieser Punkt mehr Relevanz erhalten. Zudem sollte bei der Begutachtung und der Annahme von Publikationen in Fachzeitschriften die Methodik der Literatursuche in systematischen Übersichtsarbeiten und das Vorhandensein von Suchspezialisten im Autorenteam (meist Bibliothekare) mehr Berücksichtigung finden. Article published online: 16 November 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    Improving the Quality of Care for Cancer Patients through Oncological Second Opinions in a Comprehensive Cancer Center: Feasibility of Patient-Initiated Second Opinions through a Health-Insurance Service Point

    by Carla E. Schulmeyer, Matthias W. Beckmann, Peter A. Fasching, Lothar Häberle, Henriette Golcher, Frank Kunath, Bernd Wullich, Julius Emons

    Background: To improve the quality and cost-effectiveness of care, cancer patients can obtain a second medical opinion on their treatment. Validation of the diagnostic procedure (e.g., imaging), diagnosis, and treatment recommendation allows oncological therapy to be applied in a more targeted way, optimizing interdisciplinary care. This study describes patients who received second opinions at the Comprehensive Cancer Center for Erlangen–Nuremberg metropolitan area in Germany over a 6-year period, as well as the amount of time spent on second-opinion counseling. Methods: This prospective, descriptive, single-center observational study included 584 male and female cancer patients undergoing gynecological, urologic, or general surgery who sought a second medical opinion. The extent to which the first opinion complied with standard guidelines was assessed solely descriptively. Results: The first opinion was in accordance with the guidelines and complete in 54.5% of the patients, and guideline compliant but incomplete in 13.2%. The median time taken to form a second opinion was 225 min, and the cancer information service was contacted by patients an average of eight times. Conclusions: The initial opinion was guideline compliant and complete in every second case. Without a second opinion, the remaining patients would have been denied a guideline-compliant treatment recommendation. Obtaining a second opinion gives patients an opportunity to receive a guideline-compliant treatment recommendation and enables them to benefit from newer, individualized therapeutic approaches in clinical trials. Establishing patient-initiated second opinions via central contact points appears to be a feasible option for improving guideline compliance.


  • Nieren- und Harnwegstumore

    by Stephanie Naas, Frank Kunath, Johannes Schödel